Absence of Severe Systemic Toxicity After Leakage-Controlled Isolated Limb Perfusion With Tumor Necrosis Factor-α and Melphalan
Bart C. Vrouenraets(The Netherlands Cancer Institute), Alexander M.M. Eggermont(University Medical Center Utrecht), Aernout C. Ogilvie(The Netherlands Cancer Institute), Anton J. G. Swaak(Rotterdam University of Applied Sciences), A.N. van Geel(Erasmus MC), Bin B. R. Kroon(The Netherlands Cancer Institute), Omgo E. Nieweg(The University of Sydney)
Cited by 51
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k